BIOGEN INC. Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments
BIOGEN INC. (BIIB) reported Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments of -$18.80 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments · last filed 2026-04-29
- BIOGEN INC. gain (loss) on foreign currency derivative instruments not designated as hedging instruments for the quarter ending 2026-03-31 was -$18.80M, a 344.16% decline year-over-year.
- BIOGEN INC. gain (loss) on foreign currency derivative instruments not designated as hedging instruments for the quarter ending 2025-12-31 was $68.40M.
- BIOGEN INC. gain (loss) on foreign currency derivative instruments not designated as hedging instruments for the quarter ending 2025-09-30 was $500.00K.
- BIOGEN INC. gain (loss) on foreign currency derivative instruments not designated as hedging instruments for the quarter ending 2025-06-30 was -$27.70M, a 585.96% decline year-over-year.
- BIOGEN INC. gain (loss) on foreign currency derivative instruments not designated as hedging instruments for fiscal 2025 was $33.50M.
- BIOGEN INC. gain (loss) on foreign currency derivative instruments not designated as hedging instruments for fiscal 2024 was -$49.70M, a 1407.89% decline from fiscal 2023.
- BIOGEN INC. gain (loss) on foreign currency derivative instruments not designated as hedging instruments for fiscal 2023 was $3.80M.
- BIOGEN INC. gain (loss) on foreign currency derivative instruments not designated as hedging instruments for fiscal 2022 was -$34.70M.
| Period end | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 3 month | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 3 month as first filed | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 6 month | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 6 month as first filed | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 9 month | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 9 month as first filed | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 12 month | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | -$18.80M 10-Q · filed 2026-04-29 | $49.60M derived: sum of 2 quarters · filed 2026-04-29 | $50.10M derived: sum of 3 quarters · filed 2026-04-29 | $22.40M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-12-31 | $68.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $68.90M derived: sum of 2 quarters · filed 2026-02-06 | $41.20M derived: sum of 3 quarters · filed 2026-02-06 | $33.50M 10-K · filed 2026-02-06 | ||||
| 2025-09-30 | $500.00K 10-Q · filed 2025-10-30 | -$27.20M derived: sum of 2 quarters · filed 2025-10-30 | -$34.90M 10-Q · filed 2025-10-30 | -$75.80M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-06-30 | -$27.70M 10-Q · filed 2025-07-31 | -$35.40M 10-Q · filed 2025-07-31 | -$76.30M derived: sum of 3 quarters · filed 2026-04-29 | -$99.70M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-03-31 | $7.70M 10-Q · filed 2026-04-29 | -$7.70M 10-Q · filed 2025-05-01 | -$48.60M derived: sum of 2 quarters · filed 2026-04-29 | -$72.00M derived: sum of 3 quarters · filed 2026-04-29 | -$66.30M derived: sum of 4 quarters · filed 2026-04-29 | |||
| 2024-12-31 | -$56.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | -$79.70M derived: sum of 2 quarters · filed 2026-02-06 | -$74.00M derived: sum of 3 quarters · filed 2026-02-06 | -$49.70M 10-K · filed 2026-02-06 | $49.70M 10-K · filed 2025-02-12 | |||
| 2024-09-30 | -$23.40M 10-Q · filed 2025-10-30 | $23.40M 10-Q · filed 2024-10-30 | -$17.70M derived: sum of 2 quarters · filed 2025-10-30 | $6.60M 10-Q · filed 2025-10-30 | -$6.60M 10-Q · filed 2024-10-30 | -$17.60M derived: sum of 4 quarters · filed 2026-02-06 | ||
| 2024-06-30 | $5.70M 10-Q · filed 2025-07-31 | -$5.70M 10-Q · filed 2024-08-01 | $30.00M 10-Q · filed 2025-07-31 | -$30.00M 10-Q · filed 2024-08-01 | $5.80M derived: sum of 3 quarters · filed 2026-02-06 | $28.40M derived: sum of 4 quarters · filed 2026-02-06 | ||
| 2024-03-31 | $24.30M 10-Q · filed 2025-05-01 | -$24.30M 10-Q · filed 2024-04-24 | $100.00K derived: sum of 2 quarters · filed 2026-02-06 | $22.70M derived: sum of 3 quarters · filed 2026-02-06 | $29.90M derived: sum of 4 quarters · filed 2026-02-06 | |||
| 2023-12-31 | -$24.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | -$1.60M derived: sum of 2 quarters · filed 2026-02-06 | $5.60M derived: sum of 3 quarters · filed 2026-02-06 | $3.80M 10-K · filed 2026-02-06 | ||||
| 2023-09-30 | $22.60M 10-Q · filed 2024-10-30 | -$22.60M 10-Q · filed 2023-11-08 | $29.80M derived: sum of 2 quarters · filed 2024-10-30 | $28.00M 10-Q · filed 2024-10-30 | -$28.00M 10-Q · filed 2023-11-08 | $79.10M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-06-30 | $7.20M 10-Q · filed 2024-08-01 | -$7.20M 10-Q · filed 2023-07-25 | $5.40M 10-Q · filed 2024-08-01 | -$5.40M 10-Q · filed 2023-07-25 | $56.50M derived: sum of 3 quarters · filed 2025-02-12 | $20.00M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-03-31 | -$1.80M 10-Q · filed 2024-04-24 | $49.30M derived: sum of 2 quarters · filed 2025-02-12 | $12.80M derived: sum of 3 quarters · filed 2025-02-12 | -$24.30M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2022-12-31 | $51.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $14.60M derived: sum of 2 quarters · filed 2025-02-12 | -$22.50M derived: sum of 3 quarters · filed 2025-02-12 | -$34.70M 10-K · filed 2025-02-12 | ||||
| 2022-09-30 | -$36.50M 10-Q · filed 2023-11-08 | $36.50M 10-Q · filed 2022-10-25 | -$73.60M derived: sum of 2 quarters · filed 2023-11-08 | -$85.80M 10-Q · filed 2023-11-08 | $85.80M 10-Q · filed 2022-10-25 | -$103.00M derived: sum of 4 quarters · filed 2024-02-14 | ||
| 2022-06-30 | -$37.10M 10-Q · filed 2023-07-25 | $37.10M 10-Q · filed 2022-07-20 | -$49.30M 10-Q · filed 2023-07-25 | $49.30M 10-Q · filed 2022-07-20 | -$66.50M derived: sum of 3 quarters · filed 2024-02-14 | -$80.00M derived: sum of 4 quarters · filed 2024-02-14 | ||
| 2022-03-31 | -$12.20M 10-Q · filed 2023-04-25 | -$29.40M derived: sum of 2 quarters · filed 2024-02-14 | -$42.90M derived: sum of 3 quarters · filed 2024-02-14 | -$38.10M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2021-12-31 | -$17.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$30.70M derived: sum of 2 quarters · filed 2024-02-14 | -$25.90M derived: sum of 3 quarters · filed 2024-02-14 | -$43.30M 10-K · filed 2024-02-14 | ||||
| 2021-09-30 | -$13.50M 10-Q · filed 2022-10-25 | -$8.70M derived: sum of 2 quarters · filed 2022-10-25 | -$26.10M 10-Q · filed 2022-10-25 | $25.10M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2021-06-30 | $4.80M 10-Q · filed 2022-07-20 | -$12.60M 10-Q · filed 2022-07-20 | $12.60M 10-Q · filed 2021-07-22 | $38.60M derived: sum of 3 quarters · filed 2023-02-15 | $46.40M derived: sum of 4 quarters · filed 2023-02-15 | |||
| 2021-03-31 | $17.40M 10-Q · filed 2022-05-03 | $33.80M derived: sum of 2 quarters · filed 2023-02-15 | $41.60M derived: sum of 3 quarters · filed 2023-02-15 | $49.90M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2020-12-31 | $16.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $24.20M derived: sum of 2 quarters · filed 2023-02-15 | $32.50M derived: sum of 3 quarters · filed 2023-02-15 | $30.10M 10-K · filed 2023-02-15 | -$30.10M 10-K · filed 2021-02-03 | |||
| 2020-09-30 | $7.80M 10-Q · filed 2021-10-20 | $16.10M derived: sum of 2 quarters · filed 2021-10-20 | $13.70M 10-Q · filed 2021-10-20 | $26.80M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2020-06-30 | $8.30M 10-Q · filed 2021-07-22 | -$5.90M 10-Q · filed 2021-07-22 | $5.90M 10-Q · filed 2020-07-22 | $19.00M derived: sum of 3 quarters · filed 2022-02-03 | $29.30M derived: sum of 4 quarters · filed 2022-02-03 | |||
| 2020-03-31 | $2.40M 10-Q · filed 2021-04-22 | $10.70M derived: sum of 2 quarters · filed 2022-02-03 | $21.00M derived: sum of 3 quarters · filed 2022-02-03 | $21.90M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2019-12-31 | $8.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $18.60M derived: sum of 2 quarters · filed 2022-02-03 | $19.50M derived: sum of 3 quarters · filed 2022-02-03 | -$5.90M 10-K · filed 2022-02-03 | $5.90M 10-K · filed 2020-02-06 | |||
| 2019-09-30 | $10.30M 10-Q · filed 2020-10-21 | $11.20M derived: sum of 2 quarters · filed 2020-10-21 | -$14.20M 10-Q · filed 2020-10-21 | $14.20M 10-Q · filed 2019-10-22 | $13.20M derived: sum of 4 quarters · filed 2021-02-03 | |||
| 2019-06-30 | $900.00K 10-Q · filed 2020-07-22 | -$3.90M 10-Q · filed 2020-07-22 | $3.90M 10-Q · filed 2019-07-24 | $2.90M derived: sum of 3 quarters · filed 2021-02-03 | -$2.30M derived: sum of 4 quarters · filed 2021-02-03 | |||
| 2019-03-31 | -$4.80M 10-Q · filed 2020-04-23 | $4.80M 10-Q · filed 2019-04-24 | $2.00M derived: sum of 2 quarters · filed 2021-02-03 | -$3.20M derived: sum of 3 quarters · filed 2021-02-03 | -$8.40M derived: sum of 4 quarters · filed 2021-02-03 | |||
| 2018-12-31 | $6.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $1.60M derived: sum of 2 quarters · filed 2021-02-03 | -$3.60M derived: sum of 3 quarters · filed 2021-02-03 | $2.00M 10-K · filed 2021-02-03 | ||||
| 2018-09-30 | -$5.20M 10-Q · filed 2019-10-22 | $5.20M 10-Q · filed 2018-10-23 | -$10.40M derived: sum of 2 quarters · filed 2019-10-22 | -$4.80M 10-Q · filed 2019-10-22 | $4.80M 10-Q · filed 2018-10-23 | -$5.80M derived: sum of 4 quarters · filed 2020-02-06 | ||
| 2018-06-30 | -$5.20M 10-Q · filed 2019-07-24 | $5.20M 10-Q · filed 2018-07-24 | -$400.00K 10-Q · filed 2019-07-24 | -$600.00K derived: sum of 3 quarters · filed 2020-02-06 | -$1.80M derived: sum of 4 quarters · filed 2020-02-06 | |||
| 2018-03-31 | -$5.60M 10-Q · filed 2019-04-24 | $5.60M 10-Q · filed 2018-04-24 | $4.60M derived: sum of 2 quarters · filed 2020-02-06 | $3.40M derived: sum of 3 quarters · filed 2020-02-06 | -$2.70M derived: sum of 4 quarters · filed 2020-02-06 | |||
| 2017-12-31 | $10.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $9.00M derived: sum of 2 quarters · filed 2020-02-06 | $2.90M derived: sum of 3 quarters · filed 2020-02-06 | $4.50M 10-K · filed 2020-02-06 | ||||
| 2017-09-30 | -$1.20M 10-Q · filed 2018-10-23 | $1.20M 10-Q · filed 2017-10-24 | -$7.30M derived: sum of 2 quarters · filed 2018-10-23 | -$5.70M 10-Q · filed 2018-10-23 | $5.70M 10-Q · filed 2017-10-24 | $36.90M derived: sum of 4 quarters · filed 2019-02-06 | ||
| 2017-06-30 | -$6.10M 10-Q · filed 2018-07-24 | $6.10M 10-Q · filed 2017-07-25 | -$4.50M 10-Q · filed 2018-07-24 | $4.50M 10-Q · filed 2017-07-25 | $38.10M derived: sum of 3 quarters · filed 2019-02-06 | $37.70M derived: sum of 4 quarters · filed 2019-02-06 | ||
| 2017-03-31 | -$1.60M 10-Q · filed 2018-04-24 | $1.60M 10-Q · filed 2017-04-25 | $44.20M derived: sum of 2 quarters · filed 2019-02-06 | $43.80M derived: sum of 3 quarters · filed 2019-02-06 | $62.40M derived: sum of 4 quarters · filed 2019-02-06 | |||
| 2016-12-31 | $45.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | $45.40M derived: sum of 2 quarters · filed 2019-02-06 | $64.00M derived: sum of 3 quarters · filed 2019-02-06 | $29.20M 10-K · filed 2019-02-06 | ||||
| 2016-09-30 | -$400.00K 10-Q · filed 2017-10-24 | $400.00K 10-Q · filed 2016-10-26 | $18.20M derived: sum of 2 quarters · filed 2017-10-24 | -$16.60M 10-Q · filed 2017-10-24 | $16.60M 10-Q · filed 2016-10-26 | $40.20M derived: sum of 4 quarters · filed 2018-02-01 | ||
| 2016-06-30 | $18.60M 10-Q · filed 2017-07-25 | $16.20M 10-Q · filed 2017-07-25 | $40.60M derived: sum of 3 quarters · filed 2018-02-01 | $48.70M derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2016-03-31 | $2.40M 10-Q · filed 2017-04-25 | $22.00M derived: sum of 2 quarters · filed 2018-02-01 | $30.10M derived: sum of 3 quarters · filed 2018-02-01 | $43.70M derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2015-12-31 | $19.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $27.70M derived: sum of 2 quarters · filed 2018-02-01 | $41.30M derived: sum of 3 quarters · filed 2018-02-01 | $23.80M 10-K · filed 2018-02-01 | ||||
| 2015-09-30 | $8.10M 10-Q · filed 2016-10-26 | $21.70M derived: sum of 2 quarters · filed 2016-10-26 | $4.20M 10-Q · filed 2016-10-26 | $35.40M derived: sum of 4 quarters · filed 2017-02-02 | ||||
| 2015-06-30 | $13.60M 10-Q · filed 2016-07-21 | $3.90M 10-Q · filed 2016-07-21 | $27.30M derived: sum of 3 quarters · filed 2017-02-02 | $35.00M derived: sum of 4 quarters · filed 2017-02-02 | ||||
| 2015-03-31 | $9.70M 10-Q · filed 2016-04-21 | $13.70M derived: sum of 2 quarters · filed 2017-02-02 | $21.40M derived: sum of 3 quarters · filed 2017-02-02 | $23.80M derived: sum of 4 quarters · filed 2017-02-02 | ||||
| 2014-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $11.70M derived: sum of 2 quarters · filed 2017-02-02 | $14.10M derived: sum of 3 quarters · filed 2017-02-02 | $15.50M 10-K · filed 2017-02-02 | ||||
| 2014-09-30 | $7.70M 10-Q · filed 2015-10-21 | $10.10M derived: sum of 2 quarters · filed 2015-10-21 | $11.50M 10-Q · filed 2015-10-21 | $15.40M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-06-30 | $2.40M 10-Q · filed 2015-07-24 | $3.80M 10-Q · filed 2015-07-24 | $7.70M derived: sum of 3 quarters · filed 2016-02-03 | $7.90M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-03-31 | $1.40M 10-Q · filed 2015-04-24 | $5.30M derived: sum of 2 quarters · filed 2016-02-03 | $5.50M derived: sum of 3 quarters · filed 2016-02-03 | $6.10M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2013-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $4.10M derived: sum of 2 quarters · filed 2016-02-03 | $4.70M derived: sum of 3 quarters · filed 2016-02-03 | $5.20M 10-K · filed 2016-02-03 | ||||
| 2013-09-30 | $200.00K 10-Q · filed 2014-10-22 | $800.00K derived: sum of 2 quarters · filed 2014-10-22 | $1.30M 10-Q · filed 2014-10-22 | $300.00K derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-06-30 | $600.00K 10-Q · filed 2014-07-23 | $1.50M 10-Q · filed 2014-07-23 | $100.00K derived: sum of 3 quarters · filed 2015-02-04 | $5.80M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-03-31 | $900.00K 10-Q · filed 2014-04-23 | -$500.00K derived: sum of 2 quarters · filed 2015-02-04 | $5.20M derived: sum of 3 quarters · filed 2015-02-04 | $21.10M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2012-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $4.30M derived: sum of 2 quarters · filed 2015-02-04 | $20.20M derived: sum of 3 quarters · filed 2015-02-04 | $4.20M 10-K · filed 2015-02-04 | ||||
| 2012-09-30 | $5.70M 10-Q · filed 2013-10-28 | $21.60M derived: sum of 2 quarters · filed 2013-10-28 | $5.60M 10-Q · filed 2013-10-28 | $36.20M derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2012-06-30 | $15.90M 10-Q · filed 2013-07-25 | $11.40M 10-Q · filed 2013-07-25 | $30.50M derived: sum of 3 quarters · filed 2014-02-06 | $36.60M derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2012-03-31 | $4.30M 10-Q · filed 2013-04-25 | -$4.30M 10-Q · filed 2012-05-01 | $14.60M derived: sum of 2 quarters · filed 2014-02-06 | $20.70M derived: sum of 3 quarters · filed 2014-02-06 | $21.30M derived: sum of 4 quarters · filed 2014-02-06 | |||
| 2011-12-31 | $10.30M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $16.40M derived: sum of 2 quarters · filed 2014-02-06 | $17.00M derived: sum of 3 quarters · filed 2014-02-06 | $12.10M 10-K · filed 2014-02-06 | ||||
| 2011-09-30 | $6.10M 10-Q · filed 2012-10-25 | $6.70M derived: sum of 2 quarters · filed 2012-10-25 | $1.80M 10-Q · filed 2012-10-25 | $4.80M derived: sum of 4 quarters · filed 2012-10-25 | ||||
| 2011-06-30 | $600.00K 10-Q · filed 2012-07-24 | -$4.30M 10-Q · filed 2012-07-24 | $4.30M 10-Q · filed 2011-07-26 | -$1.30M derived: sum of 3 quarters · filed 2012-07-24 | -$11.40M derived: sum of 4 quarters · filed 2012-07-24 | |||
| 2011-03-31 | -$4.90M 10-Q · filed 2012-05-01 | $4.90M 10-Q · filed 2011-04-21 | -$1.90M derived: sum of 2 quarters · filed 2012-05-01 | -$12.00M derived: sum of 3 quarters · filed 2012-05-01 | -$4.10M derived: sum of 4 quarters · filed 2012-05-01 | |||
| 2010-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | -$7.10M derived: sum of 2 quarters · filed 2012-02-03 | $800.00K derived: sum of 3 quarters · filed 2012-02-03 | $6.00M 10-K · filed 2012-02-03 | ||||
| 2010-09-30 | -$10.10M 10-Q · filed 2011-10-28 | $10.10M 10-Q · filed 2010-10-26 | -$2.20M derived: sum of 2 quarters · filed 2011-10-28 | $3.00M 10-Q · filed 2011-10-28 | ||||
| 2010-06-30 | $7.90M 10-Q · filed 2011-07-26 | $13.10M 10-Q · filed 2011-07-26 | ||||||
| 2009-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $1.10M derived: sum of 2 quarters · filed 2011-02-04 | $3.30M derived: sum of 3 quarters · filed 2011-02-04 | $2.50M 10-K · filed 2011-02-04 | ||||
| 2009-09-30 | $800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $3.00M derived: sum of 2 quarters · filed 2010-10-26 | $2.20M 10-Q · filed 2010-10-26 | |||||
| 2009-06-30 | $2.20M 10-Q · filed 2010-10-26 | $1.40M 10-Q · filed 2010-07-20 | $1.40M 10-Q · filed 2010-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |